Patrick Amstutz Appointed as Chief Executive Officer
Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the Board of Directors unanimously decided to appoint Patrick Amstutz, Ph.D., co-founder of the company, as Chief Executive Officer and to nominate him to become a member of the Board of Directors.
When Christian Zahnd resigned as CEO of Molecular Partners in November 2016, the Board of Directors appointed Patrick Amstutz as acting CEO, and engaged in a process to find the best suitable internal or external candidate. The Board of Directors is pleased to have concluded that Patrick Amstutz is best qualified to become the next CEO of the company.